Patents by Inventor Gregory P. Owens

Gregory P. Owens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the treatment of neuromyelitis optica
    Patent number: 11390667
    Abstract: The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.
    Type: Grant
    Filed: May 18, 2020
    Date of Patent: July 19, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE REGENTS OF THE UNIVERSITY OF COLORAD
    Inventors: Jeffery L. Bennett, Gregory P. Owens, Alan S. Verkman
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
    Publication number: 20210130444
    Abstract: The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.
    Type: Application
    Filed: May 18, 2020
    Publication date: May 6, 2021
    Inventors: Jeffery L. BENNETT, Gregory P. OWENS, Alan S. VERKMAN
  • Compositions and methods for the treatment of neuromyelitis optica
    Patent number: 10654916
    Abstract: The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 19, 2020
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION, THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE
    Inventors: Jeffrey L. Bennett, Gregory P. Owens, Alan S. Verkman
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA
    Publication number: 20140170140
    Abstract: The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis.
    Type: Application
    Filed: April 23, 2012
    Publication date: June 19, 2014
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION, THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE
    Inventors: Jeffrey L. Bennett, Gregory P. Owens, Alan S. Verkman
  • Systems and methods for monitoring and controlling circuit breakers
    Patent number: 7580235
    Abstract: Systems and methods for presenting information corresponding to circuit breakers and for controlling such circuit breakers are disclosed. In one embodiment, the system can include a menu-driven, pointer-accessible graphical user interface via which an operator can receive information corresponding to circuit breakers, and can automatically change the states of the circuit breakers. Menus of circuit breaker information can be organized by the state of the circuit breaker, the location of the circuit breaker, the bus to which the circuit breaker is coupled, the electrical system to which the circuit breaker belongs, and/or the system or subsystem of which the circuit breaker is a part. In further embodiments, the circuit breaker information can be organized according to custom-made arrangements.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: August 25, 2009
    Assignee: The Boeing Company
    Inventors: George H. Hamasaki, Joseph A. Sikora, Bryan P. Kesterson, Gregory P. Owens, Justin E. Hale, Norman F. Kirby, Thanh-Ha N. Herter, Michael B. McAvoy, Phuoc D. Nguyen, Robert J. Crane
  • DNA sequences encoding proteins used to elicit and detect programmed cell death
    Patent number: 5527682
    Abstract: Polypeptides and mutants and variants associated with programmed cell death in mammalian cells and DNA sequences, and fragments and derivatives thereof, encoding the polypeptides are disclosed. Also disclosed are methods for detecting programmed cell death in mammalian cells, a method of activating programmed cell death in unwanted mammalian cells, and methods for preventing unwanted cell death occurring in degenerative disorders of mammals.
    Type: Grant
    Filed: October 19, 1994
    Date of Patent: June 18, 1996
    Assignee: Regents of the University of Colorado
    Inventors: Gregory P. Owens, J. John Cohen, William E. Hahn
  • DNA sequences encoding proteins used to elicit and detect programmed cell death
    Patent number: 5360893
    Abstract: Polypeptides and mutants and variants associated with programmed cell death in mammalian cells and DNA sequences, and fragments and derivatives thereof, encoding the polypeptides are disclosed. Also disclosed are methods for detecting programmed cell death in mammalian cells, a method of activating programmed cell death in unwanted mammalian cells, and methods for preventing unwanted cell death occurring in degenerative disorders of mammals.
    Type: Grant
    Filed: July 20, 1992
    Date of Patent: November 1, 1994
    Assignee: University of Colorado Foundation, Inc.
    Inventors: Gregory P. Owens, J. John Cohen, William E. Hahn